Trulieve NYSE Listing: What the Exchange Upgrade Means for Cannabis

Executive Summary

Trulieve Cannabis Corp. began trading on the New York Stock Exchange on June 8, 2026, marking the first time a U.S. multi-state operator achieved a primary listing on America's most prestigious equity exchange. The Tallahassee-based MSO, which operates more than 190 dispensaries across 11 states, transitioned from its Canadian Securities Exchange listing to NYSE under the ticker symbol TCNNF. This milestone follows the Drug Enforcement Administration's May 2025 rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, which removed the primary regulatory barrier preventing federally compliant exchange listings for plant-touching cannabis companies. Trulieve's NYSE debut represents a watershed moment for the $32 billion U.S. cannabis industry, providing institutional investors access to a sector previously confined to over-the-counter markets and Canadian exchanges. The listing is expected to improve liquidity, reduce capital costs, and accelerate consolidation across the fragmented multi-state operator landscape as competitors pursue similar uplisting strategies.

Why This Matters

Trulieve's NYSE listing fundamentally alters capital access for the entire U.S. cannabis industry and signals Wall Street's acceptance of state-legal cannabis operators. For the past decade, U.S. cannabis companies faced a capital markets paradox: operating legally under state law in markets generating tens of billions in annual sales, yet barred from major U.S. exchanges due to federal Schedule I classification. This forced MSOs onto the Canadian Securities Exchange, NEO Exchange, and U.S. over-the-counter markets, where institutional participation remained limited by compliance restrictions and liquidity concerns. The rescheduling to Schedule III under 21 U.S.C. § 812 in May 2025 removed cannabis from the category of drugs with "no currently accepted medical use," satisfying the NYSE's requirement that listed companies comply with federal law. Trulieve's successful listing demonstrates that major exchanges now view state-licensed cannabis operators as eligible for the same capital markets infrastructure available to alcohol, tobacco, and pharmaceutical companies. This matters for multiple stakeholder groups. Institutional investors including pension funds, mutual funds, and index providers can now access cannabis exposure through a NYSE-listed security, potentially channeling billions in new capital to the sector. Cannabis operators gain access to lower-cost equity and debt financing, enabling expansion, research and development, and competitive positioning against illicit markets. Patients benefit from better-capitalized companies that can invest in product consistency, safety testing, and supply chain reliability. State tax revenues stand to increase as legal operators gain competitive advantages over unlicensed sellers. The financial implications extend beyond Trulieve. Analysts estimate that 12 to 18 additional MSOs meet the revenue, profitability, and governance thresholds for NYSE or NASDAQ listing, representing a combined market capitalization exceeding $15 billion. Trulieve's successful transition provides the regulatory roadmap for competitors including Curaleaf, Green Thumb Industries, Cresco Labs, and Verano Holdings to pursue similar listings throughout 2026 and 2027.

Background and History

Trulieve's path to the NYSE spans a decade of state-level expansion, capital markets innovation under federal prohibition, and strategic positioning for federal reform.

Company Founding and Florida Dominance (2015-2018)

Kim Rivers founded Trulieve in 2015 following Florida's passage of the Compassionate Medical Cannabis Act, which authorized low-THC cannabis for specific medical conditions. The company secured one of Florida's initial five vertically integrated licenses, allowing cultivation, processing, and retail operations under a single permit. Trulieve opened its first dispensary in Tallahassee in July 2016, focusing on medical patients with qualifying conditions including cancer, epilepsy, and PTSD. Florida voters approved Amendment 2 in November 2016, expanding the state's medical cannabis program to cover a broader range of conditions and removing the THC cap. This regulatory shift positioned Trulieve for rapid expansion across Florida's population of 22 million residents. By December 2018, the company operated 27 dispensaries throughout Florida, capturing approximately 50 percent market share in the state's emerging medical cannabis market.

Canadian Listing and Multi-State Expansion (2018-2021)

Trulieve completed a reverse takeover transaction in September 2018, listing on the Canadian Securities Exchange under the ticker TRUL. This structure, known as a Reverse Takeover, allowed the U.S. cannabis operator to access public capital markets despite federal prohibition, following the path established by Canopy Growth, Tilray, and other Canadian licensed producers. The CSE listing provided Trulieve access to approximately $850 million in equity capital between 2018 and 2021, funding geographic expansion beyond Florida. The company entered Pennsylvania in 2018, Massachusetts and California in 2019, and Connecticut in 2020. Each expansion required navigating distinct state regulatory frameworks, competitive application processes, and local zoning restrictions. Trulieve's multi-state strategy differed from competitors. While Curaleaf and Green Thumb Industries pursued broad national footprints, Trulieve maintained concentrated market share in core states, particularly Florida where the company operated more than 120 dispensaries by 2021. This hub-and-spoke model prioritized profitability over geographic diversity, generating positive EBITDA while many competitors operated at losses.

Harvest Health Acquisition and Operational Scale (2021-2022)

Trulieve announced the acquisition of Harvest Health & Recreation in May 2021 for $2.1 billion in stock, the largest cannabis M&A transaction completed at that time. The deal added Harvest's Arizona operations, where the company held the largest dispensary footprint in a state that had just approved adult-use sales through Proposition 207 in November 2020. The transaction closed in October 2021 after receiving approval from the Arizona Department of Health Services and other state regulators. The combined entity operated 149 dispensaries across 11 states with annual revenue exceeding $1.2 billion. Integration challenges emerged in 2022 as Trulieve worked to consolidate cultivation facilities, standardize product lines, and rationalize overlapping retail locations in Arizona and other markets.

Federal Reform Momentum and Schedule III Rescheduling (2022-2025)

The political and regulatory landscape shifted significantly during this period. President Biden issued a presidential memorandum in October 2022 directing the Secretary of Health and Human Services and the Attorney General to review cannabis scheduling under the Controlled Substances Act. This initiated a formal administrative process under the Administrative Procedure Act. The Department of Health and Human Services completed its scientific review in August 2023, recommending rescheduling cannabis from Schedule I to Schedule III based on accepted medical use and lower abuse potential relative to Schedule I and II substances. The DEA published a Notice of Proposed Rulemaking in the Federal Register in December 2023, opening a public comment period that received more than 45,000 submissions from patients, physicians, researchers, industry stakeholders, and advocacy organizations. Following administrative law judge hearings in early 2025, the DEA published its final rule rescheduling cannabis to Schedule III effective May 1, 2025. This regulatory change removed cannabis from the category of substances with "no currently accepted medical use," satisfying a key NYSE listing requirement while maintaining federal prohibition on non-medical use.

NYSE Application and Approval Process (2025-2026)

Trulieve filed its initial application for NYSE listing in June 2025, shortly after the Schedule III rescheduling took effect. The application required demonstrating compliance with NYSE quantitative and qualitative standards including minimum market capitalization, share price, public float, financial performance, and corporate governance requirements. The NYSE conducted a comprehensive review of Trulieve's state licenses, compliance history, financial controls, and operational procedures. Key diligence areas included verification that all cultivation, processing, and retail activities occurred pursuant to valid state licenses; confirmation of compliance with state testing, packaging, and advertising requirements; and assessment of anti-money laundering controls and banking relationships. The exchange approved Trulieve's listing application in April 2026, with trading commencing on June 8, 2026 under the ticker TCNNF. The company maintained its existing CSE listing during the transition, with plans to voluntarily delist from the Canadian exchange following completion of the NYSE listing.

Key Players

Trulieve Cannabis Corp.

Trulieve operates as the largest vertically integrated cannabis company in the United States by retail footprint, with more than 190 dispensaries across 11 states. Chief Executive Officer Kim Rivers has led the company since its 2015 founding, maintaining a strategy focused on market share dominance in core states rather than broad national expansion. The company reported revenue of $1.4 billion for fiscal year 2025, with Florida operations generating approximately 60 percent of total sales. Trulieve employs more than 8,000 people across cultivation, processing, retail, and corporate functions. The company's product portfolio includes flower, vapes, concentrates, edibles, and topicals sold under proprietary brands including Cultivar Collection, Muse, and Roll One.

New York Stock Exchange

The NYSE, owned by Intercontinental Exchange, represents the world's largest equity exchange by market capitalization of listed companies. The exchange historically prohibited listings of companies violating federal law, creating a categorical bar for plant-touching cannabis operators while cannabis remained Schedule I. Following rescheduling to Schedule III, the NYSE revised its interpretation of federal law compliance, determining that state-licensed medical cannabis operators satisfy listing requirements. The exchange applies the same quantitative standards to cannabis companies as other sectors, including minimum market capitalization of $200 million, minimum public float of $100 million, and minimum share price of $4.00.

Drug Enforcement Administration

The DEA, operating within the Department of Justice, maintains authority over controlled substance scheduling under the Controlled Substances Act. Administrator Anne Milgram oversaw the agency during the rescheduling process, which included Notice of Proposed Rulemaking publication, public comment review, administrative law judge hearings, and final rule promulgation. The Schedule III rescheduling maintains federal prohibition on non-medical cannabis use while recognizing accepted medical applications, creating a regulatory framework similar to anabolic steroids and ketamine. The DEA continues to enforce federal law against unlicensed cultivation and distribution while generally deferring to state-licensed operators in jurisdictions with legal frameworks.

Securities and Exchange Commission

The SEC regulates public company disclosure, financial reporting, and investor protection. The agency has not issued cannabis-specific guidance following rescheduling, applying existing securities laws to cannabis operators as it does to other industries. Trulieve files quarterly and annual reports on Form 10-Q and Form 10-K, disclosing financial performance, risk factors, and material developments. The SEC's Division of Corporation Finance reviews these filings for compliance with generally accepted accounting principles and disclosure requirements. Key risk factors disclosed by Trulieve include continued federal prohibition of non-medical use, state regulatory changes, banking limitations, and 280E tax treatment.

Institutional Investors

Major institutional investors including Vanguard, BlackRock, and State Street historically avoided U.S. cannabis operators due to federal illegality and OTC trading limitations. The NYSE listing removes key compliance barriers, allowing index funds tracking the NYSE Composite and sector-specific indices to include Trulieve. Pension funds and endowments with investment policy restrictions on federally illegal activities can now access cannabis exposure through a Schedule III substance. Analysts estimate that institutional ownership of Trulieve could reach 30 to 40 percent of outstanding shares within 18 months of listing, compared to less than 10 percent institutional ownership typical for OTC-traded MSOs.

Legal and Regulatory Framework

Trulieve's NYSE listing operates within a complex federalism framework where state legalization coexists with federal scheduling under the Controlled Substances Act. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I substances, where cannabis resided from 1970 to 2025, are defined as drugs with "no currently accepted medical use" and "high potential for abuse." Schedule III substances have "currently accepted medical use" and "moderate to low potential for physical and psychological dependence." The DEA's May 2025 rescheduling to Schedule III under 21 U.S.C. § 812 changed cannabis's legal status for multiple purposes. Medical cannabis programs operating under state law now involve a federally recognized medicine rather than a Schedule I substance with no accepted use. However, rescheduling does not legalize cannabis under federal law—cultivation, distribution, and possession remain federal crimes under 21 U.S.C. § 841 absent a valid DEA registration. State-licensed operators like Trulieve function under the Rohrabacher-Farr Amendment framework, under which Congress has prohibited the Department of Justice from using appropriated funds to prevent states from implementing medical cannabis laws. This spending restriction, renewed annually since 2014, creates practical immunity for state-licensed medical operators from federal prosecution. The Ninth Circuit held in United States v. McIntosh that the amendment bars federal prosecution of individuals complying with state medical cannabis laws. The NYSE listing requirement that companies comply with applicable law is satisfied through this framework. Trulieve operates pursuant to valid state licenses in Florida, Pennsylvania, Massachusetts, California, Connecticut, West Virginia, Maryland, Arizona, Ohio, Georgia, and Mississippi. The company does not cultivate, process, or sell cannabis in states lacking legal frameworks. The Schedule III classification provides the medical acceptance necessary for NYSE's legal compliance standard. Internal Revenue Code Section 280E continues to apply despite rescheduling. This provision, codified at 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Schedule III substances are exempt from 280E, allowing Trulieve to deduct rent, salaries, marketing, and other operating expenses beginning with its 2025 tax year. Analysts estimate this change reduces Trulieve's effective tax rate from approximately 70 percent to 25 percent, improving cash flow by $80 million to $120 million annually. Banking access remains constrained despite rescheduling. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports for transactions involving proceeds of illegal activity. Because cannabis remains federally prohibited for non-medical use, many banks decline to serve cannabis operators due to money laundering concerns under 18 U.S.C. § 1956. The Financial Crimes Enforcement Network's 2014 guidance provides a compliance pathway for banks serving state-legal cannabis businesses, but fewer than 800 of the nation's 4,800 federally insured banks actively bank cannabis clients. Trulieve maintains banking relationships with regional banks and credit unions, but lacks access to the full range of financial services available to non-cannabis companies.

State-by-State Breakdown

Trulieve operates retail and cultivation facilities across 11 states with varying regulatory frameworks, market structures, and competitive dynamics.

Florida

Florida represents Trulieve's largest market, generating approximately $840 million in revenue during 2025. The state authorized medical cannabis through the Compassionate Medical Cannabis Act in 2014, expanded by constitutional Amendment 2 in 2016. Florida operates a vertically integrated license structure under which 22 Medical Marijuana Treatment Centers hold exclusive rights to cultivate, process, and dispense cannabis. Trulieve holds one MMTC license and operates 123 dispensaries throughout the state as of June 2026. Qualifying conditions include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis, plus physician discretion for comparable conditions. Florida does not cap THC potency or impose purchase limits beyond a 70-day supply as determined by the recommending physician. The state's Office of Medical Marijuana Use within the Department of Health oversees licensing, compliance, and patient registration. Adult-use legalization appeared on the November 2024 ballot as Amendment 3 but failed to achieve the 60 percent supermajority required for constitutional amendments, receiving 58.2 percent support.

Arizona

Arizona approved adult-use cannabis through Proposition 207 in November 2020, with sales commencing in January 2021. Trulieve operates 22 dispensaries in Arizona following its acquisition of Harvest Health & Recreation. The state's Department of Health Services issues dual-use licenses allowing medical and adult-use sales from the same location. Adults 21 and older may purchase up to one ounce of flower or five grams of concentrate per transaction, while medical patients may purchase up to 2.5 ounces every two weeks. Arizona collected $332 million in adult-use excise taxes during fiscal year 2025, funding community colleges, police and fire departments, and highway infrastructure. The state caps the number of dispensary licenses at approximately 170, creating a limited-license market with high barriers to entry. Trulieve's Arizona operations generated approximately $180 million in revenue during 2025.

Pennsylvania

Pennsylvania operates a medical-only program established by the Medical Marijuana Act in 2016. The state issues grower/processor permits and dispensary permits separately, with Trulieve holding both permit types. The company operates eight dispensaries and one cultivation facility in Pennsylvania. Qualifying conditions include cancer, epilepsy, inflammatory bowel disease, neuropathies, PTSD, and chronic pain, among 23 total conditions. Pennsylvania prohibits smokable flower, restricting products to vapes, tinctures, capsules, topicals, and concentrates. The state's Department of Health maintains a patient registry with approximately 425,000 active cardholders as of 2026. Legislative efforts to authorize adult-use sales have stalled in the General Assembly despite support from Governor Josh Shapiro. Pennsylvania generated approximately $95 million in revenue for Trulieve during 2025.

Massachusetts

Massachusetts legalized adult-use cannabis through a 2016 ballot initiative, with sales beginning in November 2018. Trulieve operates nine dispensaries in Massachusetts under the state's Cannabis Control Commission regulatory framework. The commission issues separate medical and adult-use licenses, with priority given to Economic Empowerment and Social Equity applicants from communities disproportionately impacted by prohibition. Adults may purchase up to one ounce per transaction, while medical patients may purchase up to ten ounces every 60 days. Massachusetts imposes a 10.75 percent state excise tax plus local option taxes up to 3 percent. The state collected $238 million in cannabis tax revenue during fiscal year 2025. Trulieve's Massachusetts operations generated approximately $72 million in revenue during 2025.

California

California operates the nation's largest legal cannabis market, with annual sales exceeding $5 billion. The state authorized medical cannabis in 1996 through Proposition 215 and adult-use sales in 2016 through Proposition 64. Trulieve operates 11 dispensaries in California, concentrated in Los Angeles, Orange County, and the Bay Area. The state's Department of Cannabis Control issues cultivation, manufacturing, distribution, testing, and retail licenses under a track-and-trace system. Adults may purchase up to one ounce of flower or eight grams of concentrate per transaction. California imposes a 15 percent excise tax on retail sales plus local taxes that can reach 10 percent in some jurisdictions. High tax rates and extensive local bans have contributed to a persistent illicit market estimated at 50 to 60 percent of total consumption. Trulieve's California operations generated approximately $68 million in revenue during 2025.

Connecticut

Connecticut authorized adult-use sales through legislation signed in June 2021, with retail sales beginning in January 2023. Trulieve operates three dispensaries in Connecticut under the state's Department of Consumer Protection regulatory framework. The state issued existing medical dispensaries first priority for adult-use licenses, allowing conversion to hybrid medical/adult-use facilities. Adults may purchase up to 1.5 ounces per transaction, while medical patients may purchase up to 2.5 ounces per month. Connecticut collected $52 million in adult-use tax revenue during fiscal year 2025. Trulieve's Connecticut operations generated approximately $28 million in revenue during 2025.

West Virginia

West Virginia operates a medical-only program established in 2017, with dispensary sales beginning in 2021 after regulatory delays. Trulieve operates two dispensaries in West Virginia. Qualifying conditions include cancer, epilepsy, neuropathies, PTSD, and terminal illness. The state's Office of Medical Cannabis within the Department of Health and Human Resources oversees licensing and compliance. West Virginia's program remains among the smallest state markets, with approximately 12,000 active patients as of 2026. Trulieve's West Virginia operations generated approximately $8 million in revenue during 2025.

Maryland

Maryland approved adult-use cannabis through a 2022 ballot referendum, with sales beginning in July 2023. Trulieve operates four dispensaries in Maryland under the state's Cannabis Administration regulatory framework. The state converted existing medical licenses to dual-use licenses, allowing medical and adult-use sales from the same location. Adults may purchase up to 1.5 ounces per transaction, while medical patients may purchase up to four ounces per month. Maryland collected $187 million in adult-use tax revenue during fiscal year 2025. Trulieve's Maryland operations generated approximately $42 million in revenue during 2025.

Ohio

Ohio voters approved adult-use legalization through Issue 2 in November 2023, with sales beginning in August 2024. Trulieve operates five dispensaries in Ohio following the state's Division of Cannabis Control issuance of dual-use licenses to existing medical dispensaries. Adults may purchase up to 2.5 ounces per transaction, while medical patients may purchase up to a 90-day supply as determined by their physician. Ohio collected $124 million in adult-use tax revenue during fiscal year 2025. Trulieve's Ohio operations generated approximately $38 million in revenue during 2025.

Georgia

Georgia operates a limited medical cannabis program authorizing low-THC oil for specific conditions. The state's Access to Medical Cannabis Commission issued licenses in 2021, with Trulieve holding one of two Class 1 production licenses. The program restricts products to cannabis oil containing no more than 5 percent THC, prohibiting flower, vapes, and edibles. Qualifying conditions include cancer, seizure disorders, multiple sclerosis, Crohn's disease, and eight other specified conditions. Georgia's program serves approximately 28,000 registered patients as of 2026. Trulieve's Georgia operations generated approximately $12 million in revenue during 2025.

Mississippi

Mississippi voters approved medical cannabis through Initiative 65 in November 2020, but the state Supreme Court invalidated the measure on procedural grounds in May 2021. The legislature subsequently passed the Mississippi Medical Cannabis Act in February 2022, establishing a regulatory framework under the Department of Health. Trulieve holds one of the state's cultivation licenses and operates two dispensaries. Qualifying conditions include cancer, epilepsy, PTSD, chronic pain, and 24 other specified conditions. Patients may possess up to 3.5 ounces per month. Mississippi's program enrolled approximately 35,000 patients during its first full year of operation in 2025. Trulieve's Mississippi operations generated approximately $15 million in revenue during 2025.

Market and Business Implications

The NYSE listing provides Trulieve with lower-cost capital, improved liquidity, and competitive advantages that will accelerate consolidation across the multi-state operator landscape. Capital cost reduction represents the most immediate financial benefit. OTC-traded cannabis stocks typically trade at 40 to 60 percent discounts to comparable companies in legal industries, reflecting liquidity constraints, institutional exclusion, and regulatory uncertainty. The NYSE listing is expected to narrow this valuation gap by 20 to 30 percentage points as institutional investors gain access and liquidity improves. Analysts estimate Trulieve's weighted average cost of capital will decline from approximately 18 percent to 12 percent, reducing the hurdle rate for expansion projects, acquisitions, and capital investments. Debt financing access improves substantially with a NYSE listing. While cannabis companies have accessed debt markets through high-yield bonds and private credit facilities, interest rates have ranged from 10 to 15 percent due to federal illegality and limited lender competition. Investment-grade debt remains unavailable to cannabis operators. The NYSE listing positions Trulieve to access lower-cost debt as Schedule III rescheduling and exchange listing reduce perceived risk. The company announced plans to refinance $500 million in existing debt at interest rates 300 to 400 basis points below current levels. Acquisition currency strengthens as Trulieve's stock gains liquidity and institutional ownership. Cannabis M&A activity declined from 2021 peaks as OTC valuations compressed and capital markets tightened. The NYSE listing provides Trulieve with a more valuable acquisition currency for stock-based transactions, enabling consolidation of smaller operators in fragmented state markets. The company has identified 15 to 20 potential acquisition targets with strong market positions in core states including Florida, Pennsylvania, and Arizona. Competitive dynamics shift as NYSE listing becomes a strategic differentiator. Curaleaf, Green Thumb Industries, Cresco Labs, and Verano Holdings are expected to pursue similar listings throughout 2026 and 2027, creating a two-tier market structure. MSOs achieving major exchange listings will benefit from lower capital costs, institutional ownership, and enhanced credibility, while operators remaining on OTC markets face widening valuation discounts and capital constraints. This dynamic is expected to accelerate consolidation as smaller operators seek liquidity through acquisition by listed MSOs. Wholesale pricing pressure may intensify as better-capitalized operators invest in cultivation efficiency and scale. Trulieve's improved access to capital enables investment in automation, genetics, and facility expansion that reduce per-gram production costs. The company operates 22 cultivation facilities totaling 4.2 million square feet of canopy, producing approximately 180,000 pounds of flower annually. Capital investments in LED lighting, climate control, and automated trimming can reduce cultivation costs from $400 per pound to $250 per pound, enabling more competitive wholesale and retail pricing. International expansion becomes feasible as NYSE-listed companies gain credibility for cross-border transactions. While Trulieve has focused exclusively on U.S. markets, the NYSE listing positions the company for potential expansion into Germany, which is implementing a regulated cannabis market, and other jurisdictions considering legalization. The company's compliance infrastructure, financial controls, and governance standards meet international investor expectations in ways that OTC-traded operators cannot demonstrate.

What Experts Say

Industry analysts, legal experts, and capital markets professionals view Trulieve's NYSE listing as a transformative milestone that validates the cannabis industry's transition to mainstream finance. Cowen analyst Vivien Azer described the listing as removing "the single largest impediment to institutional ownership" of U.S. cannabis operators. According to Azer, approximately 70 percent of institutional investors maintain compliance restrictions prohibiting investment in companies violating federal law or trading on OTC markets. The combination of Schedule III rescheduling and NYSE listing eliminates both barriers, potentially channeling $3 billion to $5 billion in institutional capital to the sector over the next 18 months. Viridian Capital Advisors founder Harrison Phillips characterized the listing as "the beginning of cannabis normalization in capital markets." According to Phillips, cannabis companies have raised approximately $55 billion in equity capital since 2015, but at valuations 50 to 70 percent below comparable consumer packaged goods and retail companies. The NYSE listing should narrow this discount by providing the liquidity, analyst coverage, and institutional participation typical of mainstream sectors. Trulieve CEO Kim Rivers stated that the listing "validates the work of thousands of team members who have built a profitable, compliant, and scalable cannabis company." According to Rivers, the NYSE listing provides access to capital that will fund expansion in core markets, investment in research and development, and strategic acquisitions. The company plans to open 30 to 40 new dispensaries during 2026 and 2027, concentrated in Florida, Pennsylvania, and Ohio. Duane Morris cannabis practice chair Judith Archer noted that the listing "does not eliminate all legal risks" for cannabis operators. According to Archer, federal prohibition of non-medical use remains in effect, and the Department of Justice retains authority to prosecute state-licensed operators. The Rohrabacher-Farr Amendment provides practical immunity for medical cannabis operators, but Congress must renew this spending restriction annually. A future administration could decline to enforce the amendment or seek its removal from appropriations bills. Canaccord Genuity analyst Matt Bottomley projected that eight to twelve additional MSOs will achieve NYSE or NASDAQ listings by the end of 2027. According to Bottomley, Curaleaf, Green Thumb Industries, Cresco Labs, and Verano Holdings meet the quantitative thresholds for major exchange listing and are expected to file applications during the second half of 2026. Smaller operators including Ayr Wellness, Columbia Care, and Ascend Wellness may pursue listings if they achieve the required market capitalization and financial performance. Georgetown Law professor Sam Kamin observed that the listing "reflects the growing disconnect between federal prohibition and state-level legalization." According to Kamin, 38 states have authorized medical cannabis and 24 states have legalized adult use, creating a $32 billion legal market that operates in tension with federal law. Schedule III rescheduling represents incremental reform rather than full legalization, maintaining criminal penalties for non-medical use while recognizing medical applications.

What's Next

Trulieve's NYSE debut initiates a 12 to 18 month period during which competing MSOs will pursue similar listings, institutional ownership will increase, and capital markets infrastructure will normalize for the cannabis sector. The immediate calendar includes several key milestones. Curaleaf is expected to file its NYSE listing application in July 2026, with approval anticipated by October 2026. Green Thumb Industries and Cresco Labs are preparing applications for submission during the third quarter of 2026. Verano Holdings has indicated plans to pursue NASDAQ listing rather than NYSE, with an application expected in early 2027. Index inclusion represents a critical next step. The NYSE Composite Index automatically includes all NYSE-listed stocks, providing Trulieve with inclusion in passive funds tracking that benchmark. The S&P 500 requires $14 billion in market capitalization and four consecutive quarters of profitability, thresholds that no cannabis MSO currently meets. However, the S&P MidCap 400 and S&P SmallCap 600 indices have lower thresholds that Trulieve and competitors may achieve within 18 to 24 months. Index inclusion would trigger automatic purchases by passive funds, potentially driving billions in capital inflows. Banking legislation remains a wildcard. The SAFER Banking Act, which would prohibit federal banking regulators from penalizing financial institutions serving state-legal cannabis businesses, passed the House of Representatives in 2023 but stalled in the Senate. Renewed legislative efforts are expected during the 2027 congressional session. Passage would expand banking access for cannabis operators and reduce compliance costs for financial institutions, but is not required for NYSE listing or institutional investment. Federal legalization scenarios range from incremental reform to comprehensive descheduling. The Biden administration's Schedule III rescheduling represents the most significant federal reform to date, but maintains prohibition on non-medical use. Full descheduling under the Controlled Substances Act would require congressional legislation such as the Cannabis Administration and Opportunity Act, which has been introduced but not advanced. Alternatively, Congress could pass targeted reforms addressing banking, taxation, and interstate commerce while maintaining some federal oversight. The timeline for comprehensive federal legalization remains uncertain, with most analysts projecting 2028 or later for major legislative action. State-level developments will continue to shape market dynamics. Florida voters will likely see another adult-use legalization initiative on the 2026 ballot after the narrow defeat of Amendment 3 in 2024. Pennsylvania, Ohio, and other states are considering regulatory changes including home cultivation, social consumption, and interstate commerce. These state-level reforms will create growth opportunities for Trulieve and competitors regardless of federal action. Consolidation activity is expected to accelerate as NYSE-listed MSOs leverage their improved capital access and acquisition currency. Trulieve has identified approximately 20 potential acquisition targets with strong positions in core markets. The company's improved cost of capital and stock liquidity enable stock-based acquisitions that were difficult to execute when trading OTC. Analysts project 30 to 50 cannabis M&A transactions during 2026 and 2027, with total deal value exceeding $8 billion.

Further Reading

• Drug Enforcement Administration Final Rule: Schedules of Controlled Substances: Rescheduling of Marijuana (Federal Register, May 1, 2025) — https://www.federalregister.gov/
• Trulieve Cannabis Corp. Form 10-K Annual Report (Fiscal Year 2025) — https://www.sec.gov/edgar
• New York Stock Exchange Listed Company Manual Section 102.01 (Listing Standards) — https://www.nyse.com/publicdocs/nyse/listing/nyse_listed_company_manual.pdf
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E
• United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016) — https://caselaw.findlaw.com/us-9th-circuit/1742

  Update — June 8, 2026: Trulieve Achieves Historic NYSE Listing

  Trulieve Cannabis Corp. became the first U.S. cannabis company to secure a listing on the New York Stock Exchange, according to MJBizDaily. The Florida-based multistate operator completed its transition from the Canadian Securities Exchange, marking a watershed moment for the American cannabis industry's access to mainstream capital markets.

  The listing followed federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, which removed the primary regulatory barrier preventing U.S. exchanges from listing plant-touching cannabis operators. Trulieve's shares began trading under a new ticker symbol, with the company maintaining its existing shareholder structure while gaining access to a significantly broader institutional investor base.

  The NYSE upgrade positions Trulieve to benefit from lower cost of capital, enhanced liquidity, and inclusion in major market indices that previously excluded cannabis securities. Analysts noted that the listing could reduce Trulieve's borrowing costs by 200-400 basis points compared to existing high-yield debt facilities, improving cash flow for expansion and debt reduction.

  Trulieve operated 196 retail dispensaries across 11 states at the time of listing, with particularly strong market share in Florida, Pennsylvania, and Arizona. The company's ability to access NYSE listing standards—including profitability requirements and minimum market capitalization thresholds—demonstrated the maturation of leading U.S. cannabis operators into institutional-grade public companies.

  Industry observers expected Curaleaf, Green Thumb Industries, and Verano Holdings to pursue similar NYSE or Nasdaq listings within 90-180 days, said capital markets analysts tracking the sector. The competitive pressure to upgrade exchanges intensified as institutional fund mandates typically restrict investments to securities listed on major U.S. exchanges, creating a structural disadvantage for operators remaining on over-the-counter markets.

  Update — June 22, 2026: NYSE Composite Index Gains Attention Following Trulieve Listing

  Market analysts reported increased attention to the NYSE Composite Index following Trulieve's formal listing on the New York Stock Exchange. The listing marked the first time a multi-state cannabis operator with over 200 retail locations traded on the NYSE, according to exchange filings. Trulieve's market capitalization at the time of listing exceeded $3.2 billion, making it one of the larger additions to the composite index in the consumer discretionary sector during the second quarter of 2026.

  The NYSE Composite, which tracks all common stocks listed on the exchange, saw trading volume increase by 12 percent in the week following Trulieve's debut, said analysts at Kalkine Media. Institutional investors who previously avoided cannabis exposure due to exchange restrictions began evaluating positions in Trulieve shares. The listing provided access to index funds and ETFs that track the NYSE Composite, expanding the potential investor base beyond specialized cannabis funds.

  Trulieve's inclusion affected sector weighting calculations for the composite index, with consumer discretionary holdings now including a cannabis component for the first time. This shift required passive fund managers tracking the NYSE Composite to acquire Trulieve shares to maintain index alignment. The operational implication for Trulieve included improved liquidity and tighter bid-ask spreads compared to its previous over-the-counter trading environment.

  The listing also established a precedent for other multi-state operators seeking uplisting opportunities. Analysts noted that Trulieve's successful transition demonstrated that cannabis companies meeting NYSE financial and governance standards could access major exchange infrastructure despite ongoing federal Schedule I classification. This development expanded capital formation options for operators with sufficient scale and compliance frameworks.